- Home
- GORV vs BCTX Comparison
GORV vs BCTX Comparison
Compare GORV & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- BCTX
- Stock Information
- Founded
- GORV 1976
- BCTX 2014
- Country
- GORV United States
- BCTX Canada
- Employees
- GORV N/A
- BCTX N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- BCTX Health Care
- Exchange
- GORV Nasdaq
- BCTX Nasdaq
- Market Cap
- GORV 25.3M
- BCTX 23.5M
- IPO Year
- GORV 2015
- BCTX N/A
- Fundamental
- Price
- GORV $7.14
- BCTX $0.77
- Analyst Decision
- GORV Hold
- BCTX Strong Buy
- Analyst Count
- GORV 2
- BCTX 1
- Target Price
- GORV $2.00
- BCTX $32.00
- AVG Volume (30 Days)
- GORV 80.2K
- BCTX 1.6M
- Earning Date
- GORV 08-15-2025
- BCTX 06-16-2025
- Dividend Yield
- GORV N/A
- BCTX N/A
- EPS Growth
- GORV N/A
- BCTX N/A
- EPS
- GORV N/A
- BCTX N/A
- Revenue
- GORV $767,257,000.00
- BCTX N/A
- Revenue This Year
- GORV $15.65
- BCTX N/A
- Revenue Next Year
- GORV $20.54
- BCTX N/A
- P/E Ratio
- GORV N/A
- BCTX N/A
- Revenue Growth
- GORV N/A
- BCTX N/A
- 52 Week Low
- GORV $3.95
- BCTX $0.69
- 52 Week High
- GORV $106.80
- BCTX $29.40
- Technical
- Relative Strength Index (RSI)
- GORV 51.39
- BCTX 12.51
- Support Level
- GORV $6.49
- BCTX $1.97
- Resistance Level
- GORV $8.01
- BCTX $3.00
- Average True Range (ATR)
- GORV 0.74
- BCTX 0.25
- MACD
- GORV 0.04
- BCTX -0.17
- Stochastic Oscillator
- GORV 61.32
- BCTX 3.35
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.